Phase I Clinical Trial Center, Beijing Shijitan Hospital of Capital Medical University, Beijing, PR China (H.B., Xin.W.); State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, PR China (M.Y., J.C.); and Chinese Pharmaceutical Association, Beijing, PR China (Xia.W.)

Phase I Clinical Trial Center, Beijing Shijitan Hospital of Capital Medical University, Beijing, PR China (H.B., Xin.W.); State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, PR China (M.Y., J.C.); and Chinese Pharmaceutical Association, Beijing, PR China (Xia.W.)

Phase I Clinical Trial Center, Beijing Shijitan Hospital of Capital Medical University, Beijing, PR China (H.B., Xin.W.); State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, PR China (M.Y., J.C.); and Chinese Pharmaceutical Association, Beijing, PR China (Xia.W.)

Phase I Clinical Trial Center, Beijing Shijitan Hospital of Capital Medical University, Beijing, PR China (H.B., Xin.W.); State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, PR China (M.Y., J.C.); and Chinese Pharmaceutical Association, Beijing, PR China (Xia.W.)

Phase I Clinical Trial Center, Beijing Shijitan Hospital of Capital Medical University, Beijing, PR China (H.B., Xin.W.); State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, PR China (M.Y., J.C.); and Chinese Pharmaceutical Association, Beijing, PR China (Xia.W.)